The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Servier is set to support two research projects led by UCL to better understand the immune system’s collapse following infections from immune-inflammatory diseases.
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
Amylgen and Neuron-Experts partner to create a comprehensive offering of in-vivo and in-vitro efficacy evaluation for compounds in neurodegenerative diseases.
